Anesthetic Management Including Postoperative Regional ...
hemophilia b carrier :: Article Creator $2.9 Million Gene Therapy For Severe Hemophilia Is Approved By FDA This photo provided by BioMarin in June 2023 shows a vial and packaging for their drug Roctavian. U.S. Officials on Thursday, June 19, 2023 approved the drugmaker's gene therapy for the most common form of hemophilia, an infused treatment that can significantly reduce dangerous bleeding problems. Credit: AP WASHINGTON — U.S. Officials on Thursday approved drugmaker BioMarin's gene therapy for the most common form of hemophilia, a $2.9 million infused treatment that can significantly reduce dangerous bleeding problems. The Food and Drug Administration approved Roctavian for adult patients with severe cases of hemophilia A, the inherited blood-clotting disorder that can lead to bleeding after minor injuries or scrapes. It's the first gene therapy for those patients. The IV therapy is a long-awaited alternative to current treatment